ArticleFrontiers in digital health2026
Toward terminological clarity in digital biomarker research.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital biomarker research has generated thousands of publications demonstrating associations between sensor-derived measures and clinical conditions, yet clinical adoption remains negligible. We identify a foundational problem: the field lacks consensus on what constitutes a digital biomarker, applying identical terminology to direct physiological measurement (continuous glucose monitoring), algorithmic prediction of biological substrates (voice analysis for dopaminergic function), and purely behavioral correlates (GPS mobility and depression scores). This terminological ambiguity obscures validation requirements and prevents evidence synthesis. We argue that the "bio-" in "digital biomarker" refers to a property of the measurement itself-the marker must be derived from biology, not merely predictive of biological or clinical outcomes. Under this restrictive definition, behavioral correlates without demonstrated biological grounding, however statistically robust or clinically useful, should be designated as digital phenotypes or digital health indicators rather than biomarkers. This distinction clarifies validation pathways: biologically derived markers require technical accuracy validation against established biological reference standards; candidate biomarkers inferred from behavior require biological criterion validation before that status is claimed; behavioral indicators require outcome prediction validation. We demonstrate how this framework resolves current validation confusion and accelerates translation by aligning evidence standards with measurement types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.